Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Valuation attractive β PE of 50.9x is 48% below Healthcare median of 98.6x
Concerns1
- Net profit declined 197.6% year-over-year
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 8 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.31 K Cr | β | βΉ161.00 Cr | β | β | 7.0% | -9.1% | -197.6% |
| Mar 2024 | βΉ1.44 K Cr | β | βΉ-165.00 | β | β | -114.6% | 12.2% | -232.0% |
| Mar 2023 | βΉ1.29 K Cr | β | βΉ125.00 Cr | β | β | 40.1% | 10.8% | -132.7% |
| Mar 2022 | βΉ1.16 K Cr | β | βΉ-382.00 | β | β | -206.5% | 38.8% | 163.4% |
| Mar 2021 | βΉ837.00 Cr | β | βΉ-145.00 | β | β | -25.6% | 13.6% | -384.3% |
| Mar 2020 | βΉ737.00 Cr | β | βΉ51.00 Cr | β | β | 7.2% | 7.9% | -32.0% |
| Mar 2019 | βΉ683.00 Cr | β | βΉ75.00 Cr | β | β | 8.9% | 14.6% | 10.3% |
| Mar 2018 | βΉ596.00 Cr | β | βΉ68.00 Cr | β | β | 8.9% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,308 |
| Total Expenses | 1,195 |
| EBIT / Operating Profit | 113 |
| OPM % | 9% |
| Other Income | 122 |
| Finance Costs | 10 |
| Depreciation & Amortisation | 42 |
| Profit Before Tax | 183 |
| Tax % | - |
| Net Profit / PAT | 137 |
| EPS (βΉ) | 8.71 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limitedthis co. | βΉ6.98 K Cr | βΉ1.31 K Cr | 50.90 | 2.94 | -133.15 | -9.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |